Semaglutide vs CagriSema
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ozempic, Wegovy
A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.
Also: Semaglutide + Cagrilintide
A combination of semaglutide and cagrilintide (amylin analog) in development. Aims to provide superior weight loss through dual mechanisms.
Key Comparison Insights
- Semaglutide is FDA approved, while CagriSema remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide has stronger research evidence (FDA Approved) compared to CagriSema (Human Trials).
Detailed Comparison
| Attribute | Semaglutide | CagriSema |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1. | Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1. |
| Common Dosing | 1-2.4 mg weekly (after titration) Once weekly | Limited community data available See research protocols |
| Administration | Subcutaneous injection weekly, or oral (Rybelsus) | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Morning, same day each week | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | STEP trials demonstrated average weight loss of 15-17% body weight over 68 weeks. SELECT trial showed 20% reduction in major cardiovascular events. Proven efficacy for glycemic control in type 2 diabetes with A1C reductions of 1.5-2%. | Phase 2 trials showed up to 17.1% weight loss at 32 weeks, potentially superior to semaglutide alone. Phase 3 trials (REDEFINE program) ongoing for obesity and diabetes. |
Frequently Asked Questions: Semaglutide vs CagriSema
What is the difference between Semaglutide and CagriSema?
Semaglutide is a weight loss peptide that a glp-1 receptor agonist fda-approved for type 2 diabetes and chronic weight management. one of the most effective pharmaceutical weight loss interventions available. CagriSema is a weight loss peptide that a combination of semaglutide and cagrilintide (amylin analog) in development. aims to provide superior weight loss through dual mechanisms. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide or CagriSema?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide is typically used for weight loss purposes, while CagriSema is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide and CagriSema be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide and CagriSema together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Semaglutide and CagriSema is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.